Alnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold

On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. ALNY from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

The downgrade comes a day after Alnylam released its quarterly earnings, showing the company fell just short on the analyst EPS estimate of $1.34 with an actual EPS of $1.32. Alnylm did surpass analyst calls on its revenue, reporting $17.45 million compared to the estimate of $10.95 million.

The upside of the report boosted shares of the pharmaceutical company by nearly 14.5 percent. The stock finished at $44.96.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is down at $41.91, which is well below the average analyst target price of $67.31. Less than 2% of Vetr users are holding $ALNY in their watch lists.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechDowngradesCrowdsourcingMarketsAnalyst RatingsVetr
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...